Compile Data Set for Download or QSAR
Report error Found 83 of ic50 for UniProtKB: P51449
TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 10nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221234(US9303015, 8)
Affinity DataIC50: 16nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 18nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 28nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 31nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 39nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 58nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221235(US9303015, 9c | US9303015, 9b | US9303015, 9a)
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221233(US9303015, 7)
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 81nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 85nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221236(US9303015, 10c | US9303015, 10b | US9303015, 10a)
Affinity DataIC50: 87nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 88nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221262(US9303015, 36)
Affinity DataIC50: 89nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221236(US9303015, 10c | US9303015, 10b | US9303015, 10a)
Affinity DataIC50: 92nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 95nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221261(US9303015, 35)
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221254(US9303015, 28)
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221246(US9303015, 20)
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221229(US9303015, 3c | US9303015, 3b | US9303015, 3a)
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 140nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221243(US9303015, 17)
Affinity DataIC50: 150nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221229(US9303015, 3c | US9303015, 3b | US9303015, 3a)
Affinity DataIC50: 160nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221265(US9303015, 39)
Affinity DataIC50: 170nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 190nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 210nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221235(US9303015, 9c | US9303015, 9b | US9303015, 9a)
Affinity DataIC50: 220nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221251(US9303015, 25c | US9303015, 25b | US9303015, 25a)
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221260(US9303015, 34)
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221228(US9303015, 2c | US9303015, 2b | US9303015, 2a)
Affinity DataIC50: 260nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 270nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221236(US9303015, 10c | US9303015, 10b | US9303015, 10a)
Affinity DataIC50: 270nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221259(US9303015, 33)
Affinity DataIC50: 280nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221235(US9303015, 9c | US9303015, 9b | US9303015, 9a)
Affinity DataIC50: 300nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221242(US9303015, 16)
Affinity DataIC50: 360nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221252(US9303015, 26)
Affinity DataIC50: 360nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221228(US9303015, 2c | US9303015, 2b | US9303015, 2a)
Affinity DataIC50: 370nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221228(US9303015, 2c | US9303015, 2b | US9303015, 2a)
Affinity DataIC50: 400nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221228(US9303015, 2c | US9303015, 2b | US9303015, 2a)
Affinity DataIC50: 410nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221245(US9303015, 19)
Affinity DataIC50: 410nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221255(US9303015, 29)
Affinity DataIC50: 470nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221266(US9303015, 40)
Affinity DataIC50: 490nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221230(US9303015, 4)
Affinity DataIC50: 500nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221264(US9303015, 38)
Affinity DataIC50: 520nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221251(US9303015, 25c | US9303015, 25b | US9303015, 25a)
Affinity DataIC50: 560nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221227(US9303015, 1)
Affinity DataIC50: 670nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

Displayed 1 to 50 (of 83 total ) | Next | Last >>
Jump to: